This article is more than 5 years old. Information may no longer be current.
Trabecular micro-bypass stent lowers IOP, eases management of glaucoma
Click Here to Manage Email Alerts
CHICAGO — A trabecular micro-bypass stent implanted after cataract surgery improves the management of glaucoma, according to a speaker here.
“I believe there is a certain subset of patients that many of us will find a natural consideration for the stent,” E. Randy Craven, MD, said at Glaucoma Subspecialty Day preceding the joint meeting of the American Academy of Ophthalmology and Asia-Pacific Academy of Ophthalmology. “This may be patients you’re concerned about developing hypotony maculopathy or someone who’s had endophthalmitis or suprachoroidal hemorrhage in the opposite eye.”
E. Randy Craven
The iStent MIGS Dose-Response Study included 116 patients who received the stent and 123 patients who were randomized to cataract surgery only.
Mean IOP remained stable between 12 months and 24 months postoperatively in the stent group (17 mm Hg and 17.1 mm Hg, respectively) and increased in the control group (from 17 mm Hg to 17.8 mm Hg).
The iStent (Glaukos) was approved in June by the U.S. Food and Drug Administration for management of IOP in patients with mild to moderate open-angle glaucoma.
“When looking at how this is going to affect us in private practice or in academic situations, evaluating success early on may determine the long-term success of the stent,” Craven said.
Disclosure: Craven is a consultant for Allergan, Compulink Business Systems, Haag-Streit, Ivantis and Transcend Medical. He receives lecture fees from Alcon, Allergan and Merck and grant support from Glaukos.